Piramal Pharma Q3 Results: Firm reports Rs 90 crore loss, gets board nod to raise up to Rs 1,050 crore; shares tank 10%
Piramal Pharma said while the YoY financials are not strictly comparable due to the non-inclusion of certain "non-common control transactions" with the Piramal Enterprises Ltd (PEL), it attributed the drop in EBITDA to higher operating expenses including raw material cost, energy prices, wage inflation, and marketing cost
Disclaimer : Mytimesnow (MTN) lets you explore worldwide viral news just by analyzing social media trends. Tap read more at source for full news. The inclusion of any links does not necessarily imply any endorsement of the views expressed within them.
